Bimekizumab for Psoriatic Arthritis

[Video]

Bimekizumab is a monoclonal antibody - a laboratory-engineered protein - designed to block two specific chemical signals in the immune system: IL-17A and IL-17F. In psoriatic arthritis, these two signals drive the inflammation that attacks your joints and skin. Most older biologics only block IL-17A. Bimekizumab blocks both.

You receive it as a subcutaneous injection - under the skin - once every four weeks. Your rheumatologist may consider it whether you have never tried a biologic before (called bDMARD-naive) or whether a previous biologic, specifically a TNF inhibitor, did not work well enough for you.

Knowing this helps you ask sharper questions: not just "should I try a biologic?" but "is dual IL-17 inhibition the right fit for where my disease currently is?"

Three years of data across both trials tell a consistent story: responses that emerged in the first year held steady at year three. Here is what that looked like across the three main areas the trial measured.

ACR50 means at least a 50% improvement in joint pain and tenderness scores - a meaningful bar. Swollen joint count resolution means no measurable swelling in the joints at all. PASI 100 means complete clearance of psoriasis skin plaques. None of these are modest targets, which is what makes the sustained rates notable.

The evidence your rheumatologist is drawing on comes from two large Phase 3 clinical trials - BE OPTIMAL and BE COMPLETE - plus a long-term open-label extension called BE VITAL. Together they followed patients for three years and were published by Gossec et al. in 2026.

All patients in the active group received bimekizumab 160 mg by subcutaneous injection every four weeks. The researchers tracked joint swelling, skin clearance, physical function, and safety at multiple points across those three years. That breadth is what makes the data meaningful for a conversation with your rheumatologist - it is not a short snapshot.

One of the most practical questions when starting any biologic is: how long before I know if it is working? The trial data gives a realistic frame for that conversation.

The trial measured responses at multiple points - including year 1 and year 3 - and found that the proportion of patients achieving major outcomes was already established by year 1, then held steady through year 3. This matters because it means meaningful response is not something you wait years to see; but it also means patience through the early weeks is real.

What the table shows: responses established at year 1 are largely where they stay at year 3. There is no dramatic drop-off. For your own planning, expect your rheumatologist to want to review how you are responding somewhere in the first few months - before assuming it is or is not working.

The trial tracked every treatment-emergent adverse event across three years - meaning any health event that occurred while on bimekizumab. The headline finding: no new safety signals appeared in years 2 or 3 that were not already seen in year 1.

The rate of adverse events was measured per 100 patient-years - a standard way of accounting for different amounts of time on treatment. In biologic-naive patients the rate was 164.2 events per 100 patient-years; in TNFi-IR patients it was 88.6. Your rheumatologist will interpret what those numbers mean for your specific situation, including any other conditions or medications you are managing.

The important point for your conversation is not the raw numbers but the pattern: consistent and stable across three years. That is the kind of predictability that allows a rheumatologist to assess long-term suitability with confidence.